Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis

Weis, 2011, Tumor angiogenesis: molecular pathways and therapeutic targets, Nat. Med., 17, 1359, 10.1038/nm.2537 Isenberg, 2009, Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies, Nat. Rev. Cancer, 9, 182, 10.1038/nrc2561 Lawler, 2012, Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2, Cold Spring Harb. Perspect. Med., 2, a006627, 10.1101/cshperspect.a006627 Kaur, 2010, Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47, J. Biol. Chem., 285, 38923, 10.1074/jbc.M110.172304 Willingham, 2012, The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors, Proc. Natl. Acad Sci. USA, 109, 6662, 10.1073/pnas.1121623109 Greenaway, 2007, Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1), J. Cell. Physiol., 210, 807, 10.1002/jcp.20904 Martin-Manso, 2008, Thrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cells, Cancer Res., 68, 7090, 10.1158/0008-5472.CAN-08-0643 Campbell, 2011, ABT-898 induces tumor regression and prolongs survival in a mouse model of epithelial ovarian cancer, Mol. Cancer Ther., 10, 1876, 10.1158/1535-7163.MCT-11-0402 Greenaway, 2009, ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer, Mol. Cancer Ther., 8, 64, 10.1158/1535-7163.MCT-08-0864 Nabors, 2010, A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma, Arch. Neurol., 67, 313, 10.1001/archneurol.2010.16 Lin, 2012, Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma, J. Surg. Oncol., 106, 94, 10.1002/jso.23037 Firlej, 2011, Thrombospondin-1 triggers cell migration and development of advanced prostate tumors, Cancer Res., 71, 7649, 10.1158/0008-5472.CAN-11-0833 Nucera, 2010, B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression, Proc. Natl. Acad Sci. USA, 107, 10649, 10.1073/pnas.1004934107 Filleur, 2009, Characterization of PEDF: a multi-functional serpin family protein, J. Cell. Biochem., 106, 769, 10.1002/jcb.22072 Manalo, 2011, Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis, Mol. Carcinog., 50, 67, 10.1002/mc.20711 Zaichuk, 2004, Nuclear factor of activated T cells balances angiogenesis activation and inhibition, J. Exp. Med., 199, 1513, 10.1084/jem.20040474 Elayappan, 2009, PEDF inhibits VEGF- and EPO- induced angiogenesis in retinal endothelial cells through interruption of PI3K/Akt phosphorylation, Angiogenesis, 12, 313, 10.1007/s10456-009-9153-5 Guan, 2004, Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor, Cancer Gene Ther., 11, 325, 10.1038/sj.cgt.7700675 Cai, 2006, Decreased pigment epithelium-derived factor expression in human breast cancer progression, Clin. Cancer Res., 12, 3510, 10.1158/1078-0432.CCR-06-0094 Orgaz, 2009, Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma, Oncogene, 28, 4147, 10.1038/onc.2009.284 Ladhani, 2011, Pigment epithelium-derived factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal proteolysis, Neoplasia, 13, 633, 10.1593/neo.11446 Halin, 2004, Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors, Cancer Res., 64, 5664, 10.1158/0008-5472.CAN-04-0835 Uehara, 2004, Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma, Cancer Res., 64, 3533, 10.1158/0008-5472.CAN-03-3725 Ek, 2007, Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis, Cancer Gene Ther., 14, 616, 10.1038/sj.cgt.7701044 Fernandez-Garcia, 2007, Pigment epithelium-derived factor as a multifunctional antitumor factor, J. Mol. Med. (Berl), 85, 15, 10.1007/s00109-006-0111-z Halin, 2010, Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment, Neoplasia, 12, 336, 10.1593/neo.92046 Hanahan, 2000, Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice, J. Clin. Invest., 105, 1045, 10.1172/JCI9872 Klement, 2000, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity, J. Clin. Invest., 105, R15, 10.1172/JCI8829 Pasquier, 2010, Metronomic chemotherapy: new rationale for new directions, Nat. Rev. Clin. Oncol., 7, 455, 10.1038/nrclinonc.2010.82 Andre, 2010, Metronomic chemotherapy: back to the future!, Drug News Perspect., 23, 143, 10.1358/dnp.2010.23.2.1475913 Sistigu, 2011, Immunomodulatory effects of cyclophosphamide and implementations for vaccine design, Sem. Immunopathol., 33, 369, 10.1007/s00281-011-0245-0 Rozados, 2010, The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide, Oncol. Res., 18, 601, 10.3727/096504010X12777678141662 Doloff, 2012, VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression, Cancer Res., 72, 1103, 10.1158/0008-5472.CAN-11-3380 Bocci, 2003, Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy, Proc. Natl. Acad Sci. USA, 100, 12917, 10.1073/pnas.2135406100 Hamano, 2004, Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression, Cancer Res., 64, 1570, 10.1158/0008-5472.CAN-03-3126 Ma, 2007, Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment, Mol. Cancer Ther., 6, 2879, 10.1158/1535-7163.MCT-07-0297 Damber, 2006, The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin, Cancer Chemother. Pharmacol., 58, 354, 10.1007/s00280-005-0163-8 Laquente, 2008, Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model, Mol. Cancer Ther., 7, 638, 10.1158/1535-7163.MCT-07-2122 Iwamoto, 2011, Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma, Neoplasia, 13, 187, 10.1593/neo.101186 Jounaidi, 2006, Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11, Mol. Cancer Ther., 5, 541, 10.1158/1535-7163.MCT-05-0321 Browder, 2000, Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer, Cancer Res., 60, 1878 Jounaidi, 2001, Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy, Cancer Res., 61, 4437 Ma, 2008, Combination of antiangiogenesis with chemotherapy for more effective cancer treatment, Mol. Cancer Ther., 7, 3670, 10.1158/1535-7163.MCT-08-0715 Ma, 2009, Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib, Clin. Cancer Res., 15, 578, 10.1158/1078-0432.CCR-08-1174 Kazerounian, 2008, Thrombospondins in cancer, Cell. Mol. Life Sci., 65, 700, 10.1007/s00018-007-7486-z Yang, 2010, Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis, Invest. Ophthalmol. Vis. Sci., 51, 28, 10.1167/iovs.09-4138 Guan, 2007, Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2, Cancer Biol. Ther., 6, 419, 10.4161/cbt.6.3.3757 Abe, 2004, Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo, Am. J. Pathol., 164, 1225, 10.1016/S0002-9440(10)63210-5 Campbell, 2010, The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer, Neoplasia, 12, 275, 10.1593/neo.91880 Willett, 2004, Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer, Nat. Med., 10, 145, 10.1038/nm988 Ma, 2011, Antiangiogenesis enhances intratumoral drug retention, Cancer Res., 71, 2675, 10.1158/0008-5472.CAN-10-3242 Halama, 2011, Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines, Clin. Cancer Res., 17, 678, 10.1158/1078-0432.CCR-10-2173 Ma, 2008, Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib, Mol. Cancer Ther., 7, 79, 10.1158/1535-7163.MCT-07-0584 Yang, 2010, Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis, Cancer Biol. Ther., 9, 967, 10.4161/cbt.9.12.11635 Hackl, 2012, Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models, Gut, 62, 259, 10.1136/gutjnl-2011-301585